ATNM (Actinium Pharmaceuticals Inc) רווחיות מכירות לפי רווח גולמי

סמל תאגידי ולוגו של Actinium Pharmaceuticals Inc (ATNM)

Patent protection for radiopharmaceuticals used in bone marrow transplants provides Actinium Pharmaceuticals (ATNM) with a stable revenue stream. The commercialization strategy for Iomab-B in leukemia and active late-stage trials of targeted conjugates are driving growth. The gross margin share on GURU.Markets is based on these successes, where 96.90 forms the current metric, determining the efficiency of the business's direct cost coverage.

ATNM - שולי רווח גולמי Actinium Pharmaceuticals, Inc. בטווח 04.07.2022 - 20.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת actiniumpharma.com (ATNM)

ניתוח מסכם של החברה:Actinium Pharma (ATNM)
מוצר המיוצר על ידי Actinium Pharmaceuticals

The development of a unique radiotherapy for blood cancer provides Actinium Pharmaceuticals (ATNM) with exceptional market leverage and future pricing power. Gross margin measures the portion of revenue minus direct production costs, reflecting the efficiency of the operating model, which allows for an assessment of the gross profit margin as an indicator of the company's ability to generate profit from each unit of the drug sold.